Keros Therapeutics (KROS) Accumulated Depreciation & Amortization (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at $4.4 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 50.39% year-over-year to $4.4 million; the trailing twelve-month figure through Dec 2025 stood at $4.4 million (up 50.39% YoY), and the FY2025 full-year result was $4.4 million, up 50.39% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $4.4 million, up from $2.9 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $4.4 million in Q4 2025 and bottomed at $846000.0 in Q4 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $1.7 million (2023), against an average of $2.2 million.
• The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization gained 17.34%; it then soared 71.45% in 2024.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $846000.0 in 2021, then jumped by 37.47% to $1.2 million in 2022, then surged by 47.89% to $1.7 million in 2023, then jumped by 71.45% to $2.9 million in 2024, then surged by 50.39% to $4.4 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $4.4 million (Q4 2025), $2.9 million (Q4 2024), and $1.7 million (Q4 2023), per Business Quant data.

Peer Comparison